Mingchen HealthLtd Valuation
Is 2919 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 2919 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 002919 (CN¥31.97) wird über unserer Schätzung des Fair Value (CN¥5.23) gehandelt.
Deutlich unter dem Marktwert: 002919 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2919?
Other financial metrics that can be useful for relative valuation.
What is 2919's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥4.75b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.8x |
Enterprise Value/EBITDA | 22.3x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 2919's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 32.6x | ||
603193 Runben Biotechnology | 29.8x | 25.3% | CN¥6.2b |
603896 Zhejiang Shouxiangu Pharmaceutical | 17.6x | 15.0% | CN¥5.1b |
301507 Hangzhou Minsheng Healthcare | 52.6x | n/a | CN¥4.5b |
300791 Sirio Pharma | 30.3x | 33.9% | CN¥6.7b |
002919 Mingchen HealthLtd | 22.7x | n/a | CN¥4.8b |
Price-To-Earnings gegen Gleichaltrige: 002919 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (26.3x) mit dem Durchschnitt der anderen Unternehmen (32.9x) vergleicht.
Price to Earnings Ratio vs Industry
How does 2919's PE Ratio compare vs other companies in the CN Personal Products Industry?
Price-To-Earnings gegen Industrie: 002919 ist aufgrund seines Price-To-Earnings Verhältnisses (25.4x) im Vergleich zum CN Personal Products Branchendurchschnitt (26.3x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 2919's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 22.7x |
Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 002919 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.